Related Experiment Videos
Growth factor receptors and the progression of breast cancer
F G Kern1, A L Cheville, Y L Liu
1Vincent T. Lombardi Cancer Research Center, Georgetown University Medical Center, Washington, DC 20007.
Abstract:
Interference with autocrine or paracrine loops offers a potential means of treatment of tumors which currently lack effective therapies. Hormonally responsive breast cancers generally respond to treatment with antiestrogens but a frequent occurrence is an outgrowth of populations of tumor cells that are no longer dependent on estrogen for growth. If the acquisition of the ability to constitutively express growth factors or growth factor receptors is associated with this form of tumor progression, identification of the growth factors and their receptors having the capability of reducing the dependence on estrogen for growth is an important first step in the design of strategies aimed at interfering with their function. Experimental systems employing transfection with eukaryotic expression vectors are described that are designed to test the hypothesis that overexpression of epidermal growth factor receptor or the related protein C-ERB-B2 may confer an increased growth rate under conditions of estrogen deprivation. The transfected cells are also being used to explore the molecular mechanisms underlying the regulation of epidermal growth factor receptor expression by estrogen.
Insights
Targeting growth factor signaling may overcome estrogen independence in breast cancer. Overexpressing epidermal growth factor receptor (EGFR) or C-ERB-B2 can promote tumor growth without estrogen, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Hormonally responsive breast cancers often develop resistance to antiestrogen therapies.
- Tumor cells can become estrogen-independent by constitutively expressing growth factors or their receptors.
- Identifying these key growth factors is crucial for developing novel breast cancer treatments.
Purpose of the Study:
- To investigate if overexpression of epidermal growth factor receptor (EGFR) or C-ERB-B2 enhances tumor cell growth under estrogen-deprived conditions.
- To explore the molecular mechanisms by which estrogen regulates EGFR expression.
- To lay the groundwork for strategies targeting growth factor signaling in resistant breast cancers.
Main Methods:
- Utilizing experimental systems with eukaryotic expression vectors for cell transfection.
- Employing transfected cells to test the hypothesis of increased growth rates upon EGFR or C-ERB-B2 overexpression.
- Investigating the regulation of EGFR expression by estrogen in transfected cell lines.
Main Results:
- Overexpression of EGFR or C-ERB-B2 may confer increased growth rates in estrogen-deprived conditions.
- Transfected cells provide a model to study the transition to estrogen independence.
- Insights into the molecular mechanisms of EGFR regulation by estrogen are being gained.
Conclusions:
- Targeting autocrine/paracrine loops involving growth factors offers a potential therapeutic strategy for resistant breast cancers.
- EGFR and C-ERB-B2 are potential targets for overcoming estrogen dependence in breast cancer progression.
- Understanding growth factor receptor roles is essential for designing effective anti-cancer therapies.